On June 29, TransThera Sciences-B rose 19.89% in regular trading, trading at HKD 10.85/share, with turnover of HKD 187 million.

On the news front, the company announced on June 28 that its Board of Directors approved a plan to repurchase H shares on the open market, with a maximum total amount of RMB 100 million or its equivalent in Hong Kong dollars, pursuant to the buyback mandate approved at the annual general meeting held on June 18. The buyback plan sends a positive signal to the market amid severe share price weakness.

The announcement comes shortly after the stock suffered a dramatic collapse of over 60% on June 23 when approximately 382 million shares — representing over 90% of total share capital — became unlocked upon the company's one-year listing anniversary, triggering massive selling pressure. Additionally, the company's core product Tinengotinib has completed first patient dosing in a confirmatory Phase III cholangiocarcinoma trial, and its Phase II prostate cancer clinical trial received regulatory approval in late May, indicating continued pipeline advancement.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)